See more : Sigilon Therapeutics, Inc. (SGTX) Income Statement Analysis – Financial Results
Complete financial analysis of Panbela Therapeutics, Inc. (PBLA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Panbela Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Laramide Resources Ltd. (LAM.TO) Income Statement Analysis – Financial Results
- Hunan TV & Broadcast Intermediary Co., Ltd. (000917.SZ) Income Statement Analysis – Financial Results
- Mobix Labs, Inc. (MOBX) Income Statement Analysis – Financial Results
- LNC Technology Co., Ltd (4587.TWO) Income Statement Analysis – Financial Results
- Sphere Resources Inc. (SPHUF) Income Statement Analysis – Financial Results
Panbela Therapeutics, Inc. (PBLA)
About Panbela Therapeutics, Inc.
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.36M | 973.81K | 1.23M | 699.76K |
| Cost of Revenue | 25.65M | 35.73M | 10.01M | 5.75M | 4.32M | 3.89M | 6.02M | 5.17M | 5.44M | 595.15K | 558.47K | 691.80K | 550.54K |
| Gross Profit | -25.65M | -35.73M | -10.01M | -5.75M | -4.32M | -3.89M | -6.02M | -5.17M | -5.44M | 761.84K | 415.35K | 540.90K | 149.21K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 56.14% | 42.65% | 43.88% | 21.32% |
| Research & Development | 20.61M | 28.05M | 5.42M | 2.51M | 2.35M | 1.78M | 2.59M | 2.50M | 2.85M | 2.37K | 279.79K | 0.00 | 0.00 |
| General & Administrative | 5.03M | 6.04M | 4.59M | 3.25M | 1.97M | 2.11M | 3.42M | 2.66M | 2.81M | 837.24K | 329.88K | 258.10K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -217.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.03M | 6.04M | 4.59M | 3.25M | 1.97M | 2.11M | 3.42M | 2.66M | 2.59M | 837.24K | 329.88K | 258.10K | 253.72K |
| Other Expenses | 0.00 | -682.00K | -602.00K | 605.00K | -99.00K | -508.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 253.72K |
| Operating Expenses | 25.65M | 34.09M | 10.01M | 5.75M | 4.32M | 3.84M | 6.02M | 5.17M | 5.44M | 837.24K | 609.67K | 258.10K | 253.72K |
| Cost & Expenses | 51.29M | 34.09M | 10.01M | 5.75M | 4.32M | 3.84M | 6.02M | 5.17M | 5.44M | 1.43M | 1.17M | 949.90K | 804.26K |
| Interest Income | 123.00K | 14.00K | 1.00K | 17.00 | 2.19K | 0.00 | 1.00K | 2.00K | 8.00K | 4.00K | 18.41K | 0.00 | 0.00 |
| Interest Expense | -317.00K | 288.00K | 11.00K | 17.00K | 2.19M | 1.81M | 1.62M | 180.00K | 183.00K | 35.53K | 35.89K | 36.14K | 34.27K |
| Depreciation & Amortization | 0.00 | 16.36K | 10.01K | 5.75K | 4.32K | 3.89K | 6.02K | 5.17K | 8.00K | 9.58K | 8.79K | 5.64K | 3.10K |
| EBITDA | -51.29M | -34.76M | -10.61M | -5.15M | -4.42M | -1.76M | -6.02M | -5.17M | -5.12M | -75.40K | -194.32K | 289.44K | -101.40K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4.56% | -17.16% | 23.40% | -14.49% |
| Operating Income | -51.29M | -34.09M | -10.01M | -5.75M | -4.32M | -3.89M | -6.02M | -5.17M | -5.44M | -75.40K | -194.32K | 282.80K | -104.50K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5.56% | -19.95% | 22.94% | -14.93% |
| Total Other Income/Expenses | 25.85M | -956.00K | -613.00K | 691.00K | -2.29M | -2.27M | -4.89M | -285.00K | -564.00K | -31.53K | -17.48K | -35.14K | -33.69K |
| Income Before Tax | -25.45M | -35.05M | -10.62M | -5.06M | -6.62M | -6.16M | -10.91M | -5.45M | -5.68M | -106.92K | -211.80K | 247.66K | -138.20K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7.88% | -21.75% | 20.09% | -19.75% |
| Income Tax Expense | -186.00K | -116.00K | -488.00K | -295.00K | -415.00K | -254.00K | -536.00K | -341.00K | -756.00K | 121.00 | 220.00 | 284.00 | 115.00 |
| Net Income | -25.26M | -34.93M | -10.14M | -4.77M | -6.20M | -5.91M | -10.37M | -5.11M | -4.93M | -107.04K | -212.02K | 247.38K | -138.31K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7.89% | -21.77% | 20.07% | -19.77% |
| EPS | -232.43K | -40.75K | -20.77K | -14.80K | -26.10K | -1.52K | -3.49K | -1.97K | -4.20K | -892.03 | -1.77K | 2.06K | -1.15K |
| EPS Diluted | -232.43K | -40.75K | -20.77K | -14.80K | -26.10K | -1.52K | -3.49K | -1.97K | -4.20K | -892.03 | -1.77K | 2.06K | -1.15K |
| Weighted Avg Shares Out | 108.69 | 857.28 | 487.88 | 322.20 | 237.51 | 3.89K | 2.97K | 2.59K | 1.17K | 120.00 | 120.00 | 120.00 | 120.00 |
| Weighted Avg Shares Out (Dil) | 108.69 | 857.28 | 487.88 | 322.20 | 237.51 | 3.89K | 2.97K | 2.59K | 1.17K | 120.00 | 120.00 | 120.00 | 120.00 |
Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma
MINNEAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that US WorldMeds® 1 (USWM), a Kentucky-based specialty pharmaceutical...
Panbela Announces Publication of Abstract Titled: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors
MINNEAPOLIS, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announces the publication of preclinical data from studies of...
Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification
MINNEAPOLIS, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announces that the independent Data Safety Monitoring Board (DSMB) of the...
Panbela Therapeutics, Inc. (PBLA) Q3 2023 Earnings Call Transcript
Panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants James Carbonara - IR Jennifer Simpson - CEO Sue Horvath - CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Greetings,...
Panbela Provides Business Update and Reports Q3 2023 Financial Results
MINNEAPOLIS, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended...
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds Priced At-the-Market
MINNEAPOLIS, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has entered into agreements with certain holders of...
Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes
MINNEAPOLIS, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs announces the publication of preclinical and clinical data from studies...
Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101
MINNEAPOLIS, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced validation for the European patent 2019213664 titled "METHODS FOR...
5 Hot Penny Stocks To Watch In The Stock Market Today
Whether you're looking for the best penny stocks to buy, the most active stocks today, or just trying to plan out your next long-term investment, understanding things like stock market news and events is important.
Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication
MINNEAPOLIS, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that an abstract about SBP-101 and CPP-1X (also known...
Source: https://incomestatements.info
Category: Stock Reports